Cardiac Hypertrophy Due to Hydrocortisone Treatment in a Preterm Infant: A Case Report

Sarikabadayi Y. U., Erdeve Ö., Oguz S. S., Altug N., Dilmen U.

ERCIYES MEDICAL JOURNAL, cilt.35, sa.2, ss.93-95, 2013 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.5152/etd.2013.35
  • Dergi Adı: ERCIYES MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.93-95
  • Anahtar Kelimeler: Hydrocortisone, side effect, cardiac hypertrophy
  • Ankara Üniversitesi Adresli: Evet

Özet

Infants with chronic lung disease are at greater risk for pulmonary compromise in childhood. Hydrocortisone has been studied in the treatment of chronic lung disease. A preterm infant, with a gestational age of 26 weeks, was admitted to the neonatal intensive care unit. On the 28th postnatal day, the patient still had oxygen requirement (FiO(2) : 0.40) and hydrocortisone treatment was given for seven days. After the treatment the echocardiography revealed a remarkable thickening of the left ventricle and interventricular septum. The case reported here is the first preterm infant with cardiac hypertrophy due to hydrocortisone administration for treatment of chronic lung disease.